Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a Triple-Drug attack slow down stomach cancer?

NCT ID NCT05476796

Ongoing Disease control Sponsor: UNICANCER Source: ClinicalTrials.gov ↗

First seen Jul 24, 2026 · Last updated Jul 24, 2026

Summary

This phase 2 trial is testing whether a combination of trifluridine/tipiracil (Lonsurf) plus oxaliplatin, with or without the immunotherapy nivolumab, can help people with advanced HER2-negative stomach, esophageal, or gastroesophageal junction cancer. The study compares these combos to the standard FOLFOX regimen, also with or without nivolumab. Participants are frail patients whose cancer has spread or come back and who cannot have curative treatment. The main goal is to see if the new combinations extend the time patients live without their disease worsening.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a combination of trifluridine/tipiracil (Lonsurf), oxaliplatin, and nivolumab (Opdivo)
What this could lead to
If successful, this could offer a new chemotherapy backbone option for frail patients with advanced gastric or esophageal cancer, potentially improving progression-free survival.
What could go wrong
This is a phase 2 trial with a relatively small number of participants (118), so results may not be definitive. Combining multiple drugs also raises the risk of side effects like neuropathy and immune-related reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGUS ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adenocarcinoma Adenocarcinoma Of Esophagus esophageal adenocarcinoma gastric adenocarcinoma gastroesophageal junction adenocarcinoma Neoplasm Metastasis Recurrence

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGUS ADENOCARCINOMA GASTRIC ADENOCARCINOMA GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA

Contacts and locations

Locations

  • CH Cholet

    Cholet, 49000, France

  • CHU - Hôpital Robert Debré

    Reims, 51092, France

  • CHU Besançon - Hôpital Jean Minjoz

    Besançon, 25030, France

  • CHU Morvan

    Brest, 29200, France

  • CHU Nancy - Hôpital Brabois

    Vandœuvre-lès-Nancy, 54500, France

  • CHU Rouen - Charles Nicolle

    Rouen, 76000, France

  • CHU d'Estaing

    Clermont-Ferrand, 63100, France

  • CHU de Poitiers

    Poitiers, 86000, France

  • Centre Antoine Lacassagne

    Nice, 06189, France

  • Centre Hospitalier de Beauvais

    Beauvais, 60021, France

  • Centre Jean Perrin

    Clermont-Ferrand, 63011, France

  • Centre Léon Bérard

    Lyon, 69373, France

  • Clinique Pasteur Lanroze

    Brest, 29200, France

  • Clinique de l'Europe

    Amiens, 80000, France

  • GH Diaconesses - Crois St Simon

    Paris, 75020, France

  • Hopital Europeen Georges Pompidou

    Paris, 75015, France

  • Hopital Privé Arras Les Bonnettes

    Arras, 62000, France

  • Hôpital Nord Franche Comté

    Montbéliard, 25250, France

  • Hôpital Nord-Ouest Villefranche-sur-Saône

    Gleizé, 69400, France

  • Hôpital Saint Joseph

    Marseille, 13008, France

  • Hôpital Saint Louis

    Paris, 75010, France

  • ICO - Site René Gauducheau

    Saint-Herblain, 44805, France

  • Institut Andrée Dutreix - Clinique de Flandre

    Coudekerque-Branche, 59210, France

  • Institut Jean Godinot

    Reims, 51100, France

  • Institut Mutualiste Montsouris

    Paris, 75674, France

  • Institut Paoli Calmettes

    Marseille, 13009, France

  • Institut Sainte Catherine

    Avignon, 84000, France

  • Institut de cancérologie Strasbourg Europe

    Strasbourg, 67033, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.